Oncotarget

Research Papers:

Prognostic significance of the TREK-1 K2P potassium channels in prostate cancer

Gui-Ming Zhang _, Fang-Ning Wan, Xiao-Jian Qin, Da-Long Cao, Hai-Liang Zhang, Yao Zhu, Bo Dai, Guo-Hai Shi and Ding-Wei Ye

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:18460-18468. https://doi.org/10.18632/oncotarget.3782

Metrics: PDF 1003 views  |   HTML 1307 views  |   ?  


Abstract

Gui-Ming Zhang1,2, Fang-Ning Wan1,2, Xiao-Jian Qin1, Da-Long Cao1, Hai-Liang Zhang1, Yao Zhu1, Bo Dai1, Guo-Hai Shi1, Ding-Wei Ye1

1Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China

2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

Correspondence to:

Guo-Hai Shi, e-mail: guohaishi@126.com

Ding-Wei Ye, e-mail: yedingwei1963@126.com

Keywords: TREK-1, prostate cancer, biochemical recurrence, cell proliferation, cell cycle

Received: March 05, 2015     Accepted: April 13, 2015     Published: April 21, 2015

ABSTRACT

Background: TREK-1 channels belong to the two-pore domain potassium channel superfamily and play an important role in central nervous system diseases. However, few studies have examined their role in carcinogenesis.

Methods: In this study, we assessed the expression of TREK-1 in 100 prostate cancer (PCa) tissues using immunohistochemistry and further analyzed its clinicopathological significance. Next, cell proliferation and cell cycle analysis were carried out on human PCa PC-3 cell lines where TREK-1 was stably knockdown.

Results: We found that compared with normal prostate tissues, PCa tissues showed overexpressed TREK-1 levels and TREK-1 levels were positively associated with Gleason score and T staging. High level of TREK-1 expression was related to shorter castration resistance free survival (CRFS). Furthermore, knockdown of TREK-1 significantly inhibited PCa cell proliferation in vitro and in vivo, and induced a G1/S cell cycle arrest.

Conclusion: Our results suggest that TREK-1 might be a biomarker in CRFS judgment of PCa, as well as a potential therapeutic target.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3782